Skip to main content
Skip to navigation
Skip to search
Login icon
Login or register
Logged in
Login icon
Log out
Search
Disease areas
Acromegaly
Opioid dependence
Congresses
Publications
Science
R&D pipeline
Technology
Resources
Acromegaly
Opioid Dependence
OBAP Study Webinar 2025
Complex Patients Webinar 2026
Contact
ENEA 2026
Poster Access
Effect of long-term CAM2029 on biochemical and symptom control across a 4‑week dosing interval and during intervals >28 days
Effect of CAM2029 on long-term biochemical and symptom control in patients with acromegaly and insulin-like growth factor I (IGF-I) ≤2× upper limit of normal (ULN) grouped by prior injectable somatostatin receptor ligand (SRL) dose
